These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24637708)

  • 41. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis.
    Kim J; Yang J; Kim YB; Lee HJ; Kim S; Poo H
    Virol Sin; 2019 Oct; 34(5):563-571. PubMed ID: 31214999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection.
    Zhang D; Li H; Zhang Z; Sun S; Cheng Z; Liu J; Zhao P; Ren Q; Guo H
    Antiviral Res; 2015 Apr; 116():20-6. PubMed ID: 25637708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
    Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
    Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced production and immunological characterization of recombinant West Nile virus envelope domain III protein.
    Tripathi NK; Karothia D; Shrivastava A; Banger S; Kumar JS
    N Biotechnol; 2018 Nov; 46():7-13. PubMed ID: 29768182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice.
    Ershova AS; Gra OA; Lyaschuk AM; Grunina TM; Tkachuk AP; Bartov MS; Savina DM; Sergienko OV; Galushkina ZM; Gudov VP; Kozlovskaya LI; Kholodilov IS; Gmyl LV; Karganova GG; Lunin VG; Karyagina AS; Gintsburg AL
    BMC Infect Dis; 2016 Oct; 16(1):544. PubMed ID: 27717318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes.
    Khanam S; Etemad B; Khanna N; Swaminathan S
    Am J Trop Med Hyg; 2006 Feb; 74(2):266-77. PubMed ID: 16474083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
    Ramsauer K; Tangy F
    J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comprehensive immunoinformatics and target site study revealed the corner-stone toward Chikungunya virus treatment.
    Hasan MA; Khan MA; Datta A; Mazumder MH; Hossain MU
    Mol Immunol; 2015 May; 65(1):189-204. PubMed ID: 25682054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models.
    Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Pandey AB; Shivachandra SB
    Antiviral Res; 2017 May; 141():174-178. PubMed ID: 28259752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional characterization of recombinant major envelope protein (rB2L) of orf virus.
    Yogisharadhya R; Kumar A; Ramappa R; Venkatesan G; Bhanuprakash V; Shivachandra SB
    Arch Virol; 2017 Apr; 162(4):953-962. PubMed ID: 27995337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of a Western Equine Encephalitis recombinant E1 protein for protective immunity and diagnostics.
    Das D; Gares SL; Nagata LP; Suresh MR
    Antiviral Res; 2004 Nov; 64(2):85-92. PubMed ID: 15498603
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.
    Adam A; Luo H; Osman SR; Wang B; Roundy CM; Auguste AJ; Plante KS; Peng BH; Thangamani S; Frolova EI; Frolov I; Weaver SC; Wang T
    Emerg Microbes Infect; 2021 Dec; 10(1):305-316. PubMed ID: 33539255
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutics and vaccines against chikungunya virus.
    Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
    Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cloning, expression and evaluation of diagnostic potential of recombinant capsid protein based IgM ELISA for chikungunya virus.
    Priya R; Khan M; Rao MK; Parida M
    J Virol Methods; 2014 Jul; 203():15-22. PubMed ID: 24681089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.
    Mani S; Tripathi L; Raut R; Tyagi P; Arora U; Barman T; Sood R; Galav A; Wahala W; de Silva A; Swaminathan S; Khanna N
    PLoS One; 2013; 8(5):e64595. PubMed ID: 23717637
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
    Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
    Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
    Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
    J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction and Immunogenicity of Recombinant Vaccinia Virus Vaccine Against Japanese Encephalitis and Chikungunya Viruses Infection in Mice.
    Zhang Y; Han JC; Jing J; Liu H; Zhang H; Li ZH; Jin NY; Lu HJ
    Vector Borne Zoonotic Dis; 2020 Oct; 20(10):788-796. PubMed ID: 32584657
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.
    Jaiswal S; Khanna N; Swaminathan S
    Protein Expr Purif; 2004 Jan; 33(1):80-91. PubMed ID: 14680965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.